… Care Medicine, Zhongda Hospital, School of Medicine, … consequently, randomized controlled trials furnish the higher … a randomized control trial, treatment success was nonsignificantly … imipenem/cilastatin and imipenem/relebactam in the treatment …

… in the document stating that at least … clavulanic acid; 0% against carbapenems (imipenem, ertapenem) and polymyxins (colistin … human medicine, colistin has long been excluded from treatment protocols … Naturelles, École doctorale ED589. Thèse de Doctorat de l’ …

… , ceftazidime, ceftazidime-avibactam, imipenem, meropenem, gentamicin, levofloxacin … revealing its extensive drug resistance, plasmid-mediated … Research of Kunming Medical University (Grant No … epidemiology, genetic context, treatment options, and detection …

… into refractory infections and treatment failure. Examination of … accordance with the medical research regulations of the … and therapeutic implications. Microb Biotechnol. 2024;17(5). … pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob Agents …

… using MEM alone, while different drug treatments did not significantly affect the … , and resistance spectra among various medical institutions, further verification of the … , New Delhi metallo-β-lactamase; IMP, imipenem hydrolysing MBL; RT, retention time; …

… randomized, double-blind PIVOT-PO trial (NCT06059846) compared oral tebipenem … with 60.2% for imipenem-cilastatin (adjusted treatment difference: −1.3%; … diseases at Sharp Rees-Stealy Medical Group. “The therapeutic … HBr data to the FDA in the fourth quarter …

… combinations.” A phase 3 trial of tebipenem hydrobromide (HBr), … yielded positive results. The medication’s overall success rate “ … 2% for imipenem-cilastatin, for an adjusted treatment difference of … similar to that of imipenem-cilastatin and other carbapenems …

… tebipenem HBr toward FDA submission and bringing … Diseases Sharp Rees Stealy Medical Group, commented: “Increasing … to patients and improving treatment options.” Secondary endpoints … drug) in patients with qualifying pathogens susceptible to imipenem. The trial …

… at Sharp Rees Stealy Medical Group, stated, “Increasing … patients and improving treatment options.” Trial design and efficacy … imipenem-cilastatin (291/483 participants), with an adjusted treatment … and oral options for drug-resistant infections are limited …

Drugmaker GSK made two key updates … Monday, with positive phase III trial results for tebipenem HBr, an … trial had demonstrated non-inferiority of oral tebipenem HBr versus intravenous imipenem … Separately, GSK said the European Medicines Agency's CHMP had …